Affordable Access

deepdyve-link
Publisher Website

Enhanced immunotherapy of SM5-1 in hepatocellular carcinoma by conjugating with gold nanoparticles and its in vivo bioluminescence tomographic evaluation.

Authors
  • Ma, Xibo1
  • Hui, Hui2
  • Jin, Yushen3
  • Dong, Di2
  • Liang, Xiaolong4
  • Yang, Xin2
  • Tan, Ke5
  • Dai, Zhifei4
  • Cheng, Zhen6
  • Tian, Jie7
  • 1 Key Laboratory of Molecular Imaging of Chinese Academy of Sciences, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, China; Molecular Imaging Program at Stanford (MIPS), Bio-X Program, Department of Radiology, Stanford University, CA, 94305-5344, USA; Beijing Key Laboratory of Molecular Imaging, Beijing, 100190, China. , (China)
  • 2 Key Laboratory of Molecular Imaging of Chinese Academy of Sciences, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, China; Beijing Key Laboratory of Molecular Imaging, Beijing, 100190, China. , (China)
  • 3 Nanomedicine and Biosensor Laboratory, School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150080, China. , (China)
  • 4 Department of Biomedical Engineering, College of Engineering, Peking University, Beijing, 100871, China. , (China)
  • 5 Educational Technology Center, The Chinese PLA General Hospital, 100853, Beijing, China. , (China)
  • 6 Molecular Imaging Program at Stanford (MIPS), Bio-X Program, Department of Radiology, Stanford University, CA, 94305-5344, USA. Electronic address: [email protected]
  • 7 Key Laboratory of Molecular Imaging of Chinese Academy of Sciences, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, China; Beijing Key Laboratory of Molecular Imaging, Beijing, 100190, China. Electronic address: [email protected] , (China)
Type
Published Article
Journal
Biomaterials
Publication Date
May 01, 2016
Volume
87
Pages
46–56
Identifiers
DOI: 10.1016/j.biomaterials.2016.02.007
PMID: 26897539
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

SM5-1 is a humanized mouse monoclonal antibody, targeting an over-expressed membrane protein of approximately 230 kDa in hepatocellular carcinoma (HCC). SM5-1 can be used for target therapy in hepatocellular carinoma due to its ability of inhibiting cell growth and inducing apoptosis. However, the tumor inhibition efficacy of SM5-1 in HCC cancer treatment remains low. In this study, we synthesized SM5-1-conjugated gold nanoparticles (Au-SM5-1 NPs) and investigated their anticancer efficacy in HCC both in vitro and in vivo. The tumor inhibition rates of Au-SM5-1 NPs for subcutaneous tumor mice were 40.10% ± 4.34%, 31.37% ± 5.12%, and 30.63% ± 4.87% on day 12, 18, and 24 post-treatment as determined by bioluminescent intensity. In addition, we investigated the antitumor efficacy of Au-SM5-1 NPs in orthotopic HCC tumor models. The results showed that the inhibition rates of Au-SM5-1 NPs can reach up to 39.64% ± 4.87% on day 31 post-treatment determined by the bioluminescent intensity of the abdomen in tumor-bearing mice. Furthermore, three-dimensional reconstruction results of the orthotopic tumor revealed that Au-SM5-1 NPs significantly inhibited tumor growth compared with SM5-1 alone. Our results suggested that the developed Au-SM5-1 NPs has great potential as an antibody-based nano-drug for HCC therapy. Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

Report this publication

Statistics

Seen <100 times